Jefferies analyst Matthew Stanton, CFA maintained a Buy rating on Maravai Lifesciences Holdings (MRVI – Research Report) yesterday and set a price target of $10.00.
Matthew Stanton, CFA has given his Buy rating due to a combination of factors influencing Maravai Lifesciences Holdings. Despite the recent challenges, such as the decline in gross margins and revenue misses, the company has shown resilience with its strategic financial decisions, including the pre-payment of $228 million in debt, which indicates strong cash management and a solid financial position.
Furthermore, the anticipation of future growth, particularly with the upcoming guidance for 2025, suggests potential upside. The focus on foundational growth of the base business and the strategic importance of their CleanCap technology, despite current forecasting difficulties, also contribute to the positive outlook. Additionally, the company’s involvement in the promising CAR-T cell and gene therapy market, as evidenced by the use of Cygnus HCP assay in FDA/EMA approved therapies, underscores its potential for future success.
MRVI’s price has also changed dramatically for the past six months – from $9.160 to $2.580, which is a -71.83% drop .
Questions or Comments about the article? Write to editor@tipranks.com